CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$300.02−0.13 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $14.41B
- P/E (TTM)
- –
- Dividend yield
- –
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DSA | $2.40B | $2.41B | $2.40B | $2.41B | $2.43B | $2.44B | $2.45B | $2.47B | $2.52B | $2.56B | $2.62B | $2.68B | 59.9% | -1.4% |
| RMS | $837.58M | $841.38M | $846.08M | $844.08M | $828.43M | $821.54M | $829.38M | $820.90M | $809.93M | $813.48M | $792.34M | $792.67M | 20.9% | +1.1% |
| Manufacturing | $765.72M | $778.46M | $766.41M | $764.96M | $771.14M | $762.62M | $769.33M | $766.30M | $745.17M | $739.39M | $721.44M | $741.59M | 19.1% | -0.7% |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DSA | $436.10M | $434.48M | $424.56M | $402.75M | $406.03M | $421.62M | $442.51M | $505.94M | $526.32M | $549.48M | $606.08M | $636.76M | +7.4% |
| Segment operating income | $412.04M | $356.39M | $284.84M | $391.27M | $387.81M | $422.74M | $485.47M | – | – | – | – | – | +6.2% |
| RMS | $51.23M | $50.74M | $44.57M | $127.71M | $120.71M | $114.87M | $114.41M | $137.65M | $138.44M | $157.41M | $154.67M | $154.76M | -57.6% |
| Manufacturing | -$75.28M | -$128.83M | -$184.28M | -$139.19M | -$138.92M | -$113.75M | -$71.45M | $146.64M | $132.73M | $119.90M | $88.33M | $79.52M | -45.8% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of services provided (excluding amortization of intangible assets) | $3.22B | $3.25B | $3.25B | $3.26B | $3.28B | $3.29B | $3.30B | $3.33B | $3.37B | $3.40B | $3.44B | $3.50B | 80.5% | -2.0% |
| Product | $781.21M | $776.72M | $765.28M | $764.99M | $745.48M | $737.40M | $745.85M | $730.69M | $710.25M | $712.08M | $689.39M | $713.06M | 19.5% | +4.8% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.14B | $2.15B | $2.14B | $2.17B | $2.19B | $2.21B | $2.24B | $2.24B | $2.27B | $2.30B | $2.35B | $2.46B | 53.5% | -2.5% |
| Europe | $1.10B | $1.12B | $1.10B | $1.09B | $1.08B | $1.07B | $1.08B | $1.09B | $1.08B | $1.09B | $1.08B | $1.08B | 27.5% | +2.1% |
| Canada | $477.16M | $485.24M | $501.03M | $497.11M | $507.39M | $497.05M | $482.09M | $492.76M | $494.70M | $487.10M | $487.31M | $475.72M | 11.9% | -6.0% |
| Asia Pacific | $224.58M | $218.56M | $205.02M | $203.89M | $197.24M | $193.12M | $196.95M | $199.09M | $194.32M | $203.79M | $200.83M | $196.76M | 5.6% | +13.9% |
| Other | $60.38M | $57.59M | $64.87M | $65.20M | $55.38M | $52.74M | $52.82M | $44.80M | $35.80M | $30.79M | $16.85M | $10.35M | 1.5% | +9.0% |
From the segment and revenue-disaggregation notes of Charles River Laboratories International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.